Immunopathology of leishmaniasis: An update

International Journal of Immunopathology and Pharmacology

Volumn 20, Issue 3, 2007, Pages 435-445

  Mansueto, P ^a   Vitale, G ^a   Di Lorenzo, G ^a   Rini, G B ^a   Mansueto, S ^a   Cillari, Enrico ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b VILLA SOFIA CERVELLO HOSPITAL   (Italy)

Author keywords

Apoptosis; Chemokines; Cutaneous leishmaniasis; Cytokines; TH1 T H2 paradigm; Visceral leishmaniasis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 4;

ANTIGEN SPECIFICITY; CD8+ T LYMPHOCYTE; DISEASE COURSE; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFECTION CONTROL; LEISHMANIA; LEISHMANIASIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

EID: 34948830086     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200702000302     Document Type: Review

References (80)

1. Dantas-Torres F. and S.P. Brandao-Filho. 2006. Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control. Rev. Inst. Med. Trop. Sao Paulo 48:151.
2. Bern C. and R. Chowdhury. 2006. The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J. Med. Res. 123:275.
3. Steffen R., M. Rickenbach, U. Wilhelm, A. Helminger and M. Schar. 1987. Health problems after travel to developing countries. J. Infect. Dis. 156:84.
4. Murray H.W., J.D. Berman, C.R. Davies and N.G. Saravia. 2005. Advances in leishmaniasis. Lancet 366:1561.
5. Croft S.L., L. Vivas and S. Brooker. 2003. Recent advances in research and control of malaria, leishmaniasis, trypanosomiasis and schistosomiasis. East Mediterr. Health J. 9:518.
6. Thomaz-Soccol V., G. Lanotte, J.A. Rioux, F. Pratlong, A. Martini-Dumas and E. Serres. 1993. Phylogenetic taxonomy of New World Leishmania. Ann. Parasitol. Hum. Comp. 68:104.
7. Gramiccia M. and L. Gradoni. 2005. The current status of zoonotic leishmaniases and approaches to disease control. Int. J. Parasitol. 35:1169.
8. Bates P.A. and M.E. Rogers. 2004. New insights into the developmental biology and transmission mechanisms of Leishmania. Curr. Mol. Med. 4:601.
9. Colmenares M., S. Kar, K. Goldsmith-Pestana and D. McMahon-Pratt. 2002. Mechanisms of pathogenesis: differences amongst Leishmania species. Trans. R. Soc. Trop. Med. Hyg. 96.S3.
10. Gumy A., J.A. Louis and P. Launois. 2004. The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds. Int. J. Parasitol. 34:433.
11. Louis J.A., A. Gumy, H. Voigt, P. Launois and M. Rocken. 2003. The use of the murine model of infection with Leishmania major to reveal the antagonistic effects that IL-4 can exert on T helper cell development and demonstrate that these opposite effects depend upon the nature of the cells targeted for IL-4 signaling. Pathol. Biol. 51:71.
12. Vannier-Santos M.A., A. Martiny and W. de Souza. 2002. Cell biology of Leishmania spp.: invading and evading. Curr. Pharm. Des. 8:297.
13. McSorley S., L. Proudfoot, C.A. O'Donnell and F.Y. Liew. 1996. Immunology of murine leishmaniasis. Clin. Dermatol. 14:451.
14. Barbieri C.L. 2006. Immunology of canine leishmaniasis. Parasite Immunol. 28:329.
15. Roberts M.T. 2006. Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment. Br. Med. Bull. 75:115.
16. Steigerwald M. and H. Moll. 2005. Leishmania major modulates chemokine and chemokine receptor expression by dendritic cells and affects their migratory capacity. Infect. Immun. 73:2564.
17. Ritter U. and H. Moll. 2000. Monocyte chemotactic protein-1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN-gamma and is antagonized by IL-4. Eur. J. Immunol. 30:3111.
18. Constantinescu C.S., B.D. Hondowicz, M.M. Elloso, M. Wysocka, G. Trinchieri and P. Scott. 1998. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. Eur. J. Immunol. 28:2227.
19. Kemp M., J.A. Kurtzhals, K. Bendtzen, L.K. Poulsen, M.B. Hansen, D.K. Koech, A. Kharazmi and T.G. Theander. 1993. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect. Immun. 61:1069.
20. Chtanova T. and C.R. Mackay. 2001. T cell effector subsets: extending the Th1/Th2 paradigm. Adv. Immunol. 78:233.
21. Bacellar O., A. D'oliveira Jr., S. Jeronimo and E.M. Carvalho. 2000. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 12:1228.
22. Murray H.W., C.W. Tsai, J. Liu and X. Ma. 2006. Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18. Infect. Immun. 74:4370.
23. Arris D., L.M. Johnson, K. Joyce, C. Saris, A. Villarino, C.A. Hunter and P. Scott. 2004. Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J. Immunol. 172:4672.
24. Elloso M.M. and P. Scott. 1999. Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection. J. Immunol. 162:6708.
25. Padigel U.M. and J.P. Farrell. 2003. CD40-CD40 ligand costimulation is not required for initiation and maintenance of a Th1-type response to Leishmania major infection. Infect. Immun. 71:1389.
26. Holzmuller P., R. Bras-Goncalves and J.L. Lemesre. 2006. Phenotypical characteristics, biochemical pathways, molecular targets and putative role of nitric oxide-mediated programmed cell death in Leishmania. Parasitology 132.S19.
27. Liew F.Y., X.Q. Wei and L. Proudfoot. 1997. Cytokines and nitric oxide as effector molecules against parasitic infections. Phil. Trans. R. Soc. Lond. B. 352:1311.
28. Al-Zamel F., F.J. Al-Shammary, S. El-Shewemi and R. Soliman. 1996. Enhancement of leishmanicidal activity of human macrophages against Leishmania major and Leishmania donovani infection using recombinant human granulocyte macrophage colony stimulating factor. Zentralbl. Bakteriol. 285:92.
29. Nunes M.P., L. Cysne-Finkelstein, B.C. Monteiro, D.M. de Souza, N.A. Gomes and G.A. DosReis. 2005. CD40 signaling induces reciprocal outcomes in Leishmania-infected macrophages; roles of host genotype and cytokine milieu. Microbes Infect. 7:78.
30. Eidsmo L., S. Nylen, A. Khamesipour, M.A. Hedblad, F. Chiodi and H. Akuffo. 2005. The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis. Am. J. Pathol. 166:1099.
31. Potestio M., P. D'Agostino, G.C. Romano, S. Milano, V. Ferlazzo, A. Aquino, G. Di Bella, R. Caruso, G. Gambino, G. Vitale, S. Mansueto and E. Cillari. 2004. CD4+ CCR5+ and CD4+ CCR3+ lymphocyte subset and monocyte apoptosis in patients with acute visceral leishmaniasis. Immunology 113:260.
32. Belkaid Y. 2003. The role of CD4(+)CD25(+) regulatory T cells in Leishmania infection. Expert Opin. Biol. Ther. 3:875.
33. Kariminia A., E. Bourreau, H. Pascalis, P. Couppie, D. Sainte-Marie, F. Tacchini-Cottier and P. Launois. 2005. Transforming growth factor beta 1 production by CD4+ CD25+ regulatory T cells in peripheral blood mononuclear cells from healthy subjects stimulated with Leishmania guyanensis. Infect. Immun. 73:5908.
34. Aguilar-Torrentera F. and Y. Carlier. 2001. Immunological factors governing resistance and susceptibility of mice to Leishmania major infection. Rev. Latinoam. Microbiol. 43:135.
35. Sacks D.M and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845.
36. Noben-Trauth N., R. Lira, H. Nagase, W.E. Paul and D.L. Sacks. 2003. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J. Immunol. 170:5152.
37. Matthews D.J., C.L. Emson, G.J. McKenzie, H.E. John, J.M. Blackwell and A.N. McKenzie. 2000. IL-13 is a susceptibility factor for Leishmania major infection. J. Immunol. 164:1458.
38. Li J., C.A. Hunter and J.P. Farrell. 1999. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J. Immunol. 162:974.
39. Shankar A.H. and R.G. Titus. 1997. The influence of antigen-presenting cell type and interferon-gamma on priming and cytokine secretion of Leishmania major-specific T cells. J. Infect. Dis. 175:151.
40. Chakir H., A. Campos-Neto, M. Mojibian and J.R. Webb. 2003. IL-12Rbeta2-deficient mice of a genetically resistant background are susceptible to Leishmania major infection and develop a parasite-specific Th2 immune response. Microbes Infect. 5:241.
41. Alexander J. and K. Bryson. 2005. T helper (h)1/ Th2 and Leishmania: paradox rather than paradigm. Immunol. Lett. 99:17.
42. Denise H., K. McNeil, D.R. Brooks, J. Alexander, G.H. Coombs and J.C. Mottram. 2003. Expression of multiple CPB genes encoding cysteine proteases is required for Leishmania mexicana virulence in vivo. Infect. Immun. 71:3190.
43. Ueda-Nakamura T., M. da Conceicao Rocha Sampaio, N.L. Cunha-e-Silva, Y.M. Traub-Cseko and W. de Souza. 2002. Expression and processing of megasome cysteine proteinases during Leishmania amazonensis differentiation. Parasitol. Res. 88:332.
44. Cameron P., A. McGachy, M. Anderson, A. Paul, G.H. Coombs, J.C. Mottram, J. Alexander and R. Plevin. 2004. Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cysteine peptidases and the NF-kappaB signaling pathway. J. Immunol. 173:3297.
45. Kaye P.M., A.J. Curry and J.M. Blackwell. 1991. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:2763.
46. Cillari E., G. Vitale, F. Arcoleo, P. D'Agostino, C. Mocciaro, G. Gambino, R. Malta, G. Stassi, C. Giordano and S. Milano. 1995. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 7:740.
47. Ansari N.A., S. Saluja and P. Salotra. 2006. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Clin. Immunol. 119:339.
48. Vitale G., G. Reina, S. Mansueto, R. Malta, G. Gambino, C. Mocciaro, R. D'Agostino, M. Dieli and E. Cillari. 1992. The significance of serum soluble IL-2 receptor as a marker for active visceral leishmaniasis in Sicilian patients. Clin. Exp. Immunol. 90:219.
49. Cillari E., F.Y. Liew, P. Lo Campo, S. Milano, S. Mansueto and A. Salerno. 1988. Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily. J. Immunol. 140:2721.
50. Cillari E., S. Milano, M. Dieli, E. Maltese, S. Di Rosa, S. Mansueto, A. Salerno and F.Y. Liew. 1991. Reduction in the number of UCHL-1+ cells and IL-2 production in the peripheral blood of patients with visceral leishmaniasis. J. Immunol. 146:1026.
51. Carvalho E.M., R. Badaro, S.G. Reed, T.C. Jones and W.D. Johnson. 1985. Absence of gamma interferon and interleukin-2 production during active visceral leishmaniasis. J. Clin. Invest. 76:2066.
52. Ghalib H.W., M.R. Piuvezam, Y.A. Skeiky, M. Siddig, F.A. Hashim, A.M. el-Hassan, D.M. Russo and S.G. Reed. 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Invest. 92:324.
53. Carvalho E.M., O. Bacelar, C.E. Brownell, T. Regis, R.L. Coffman and S.G. Reed. 1994. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152:5949.
54. Ghalib H.W., J.A. Whittle, M. Kubin, F.A. Hashim, A.M. el-Hassan, K.H. Grabstein, G. Trinchieri and S.G. Reed. 1995. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J. Immunol. 154:4623.
55. Kurkjian K.M., A.J. Mahmutovic, K.L. Kellar, R. Haque, C. Bern and W.E. Secor. 2006. Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 69:353.
56. Kemp M., T.G. Theander and A. Kharazmi. 1996. The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Immunol. Today 17:13.
57. Romagnani S. 1997. The T1l/Th2 paradigm. Immunol. Today 18:263.
58. Woldmann T.A. and Y. Tagaya. 1999. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17:19.
59. Lauwerys B.R., N. Garot, J.C. Renauld and F.A. Houssian. 2000. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J. Immunol. 165:1847.
60. Loza M.J., L. Zamai, L. Azzoni, E. Rosati and B. Perussia. 2002. Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood 99: 1273.
61. Milano S., G. Di Bella, P. D'Agostino, C. Barbera, R. Caruso, M. La Rosa, V. Ferlazzo, G. Vitale, C. La Russa, G. Gambino, N. Chifari, S. Mansueto and E. Cillari. 2002. IL-15 in human visceral leishmaniasis caused by Leishmania infantum. Clin. Exp. Immunol. 127:360.
62. D'Agostino P., S. Milano, F. Arcoleo, G. Di Bella, M. La Rosa, V. Ferlazzo, R. Caruso, N. Chifari, G. Vitale, S. Mansueto and E. Cillari. 2004. Interleukin-15, as interferon-gamma, induces the killing of Leishmania infantum in phorbol-myristate-acetate-activated macrophages increasing interleukin-12. Scand. J. Immunol. 60:609.
63. Lehmann J., K.H. Enssle, I. Lehmann, A. Emmendorfer and M.L. Lohmann-Matthes. 2000. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J. Interferon Cytokine Res. 20:63.
64. Satoskar A., H. Bluethmann and J. Alexander. 1995. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63: 4894.
65. Stager S., J. Alexander, K.C. Carter, F. Brombacher and P.M. Kaye. 2003. Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect. Immun. 71:4804.
66. Wilson M.E., B.M. Young, B.L. Davidson, K.A. Mente and S.E. McGowan. 1998. The importance of TGF-beta in murine visceral leishmaniasis. J. Immunol. 161:6148.
67. Murray H.W., K.C. Flanders, D.D. Donaldson, J.P. Sypek, P.J. Gotwals, J. Liu and X. Ma. 2005. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 73:3903.
68. Gollob K.J., L.R. Antonelli and W.O. Dutra. 2005. Insights into CD4+ memory T cells following Leishmania infection. Trends Parasitol. 21:347.
69. Hailu A., D. van Baarle, G.J. Knol, N. Berhe, F. Miedema and P.A. Kager. 2005. T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin. Immunol. 117:182.
70. Estaquier J., T. Idziorek, W. Zou, D. Emilie, C.M. Farber, J.M. Bourez and J.C Ameisen. 1995. T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J. Exp. Med. 182:1759.
71. Dockrell D.H. 2001. Apoptotic cell death in the pathogenesis of infectious diseases. J. Infect. 42: 227.
72. Sereti I., B. Herpin, J.A. Metcalf, R. Stevens, M.W. Baseler, C.W. Hallahan, J.A. Kovacs, R.T. Davey and H.C. Lane. 2001. CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. AIDS 15:1765.
73. Das G., H. Vohra, K. Rao, B. Saha and G.C. Mishra. 1999. Leishmania donovani infection of a susceptible host results in CD4+ T-cell apoptosis and decreased Th1 cytokine production. Scand. J. Immunol. 49:307.
74. Conceicao-Silva F., M. Hahne, M. Schroter, J. Louis and J. Tschopp. 1998. The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity. Eur. J. Immunol. 28:237.
75. Alexander C.E., P.M. Kaye and C.R. Engwerda. 2001. CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice. Eur. J. Immunol. 31:1199.
76. Bertho A.L., M.A. Santiago, A.M. Da-Cruz and S.G. Coutinho. 2000. Detection of early apoptosis and cell death in T CD4+ and CD8+ cells from lesions of patients with localized cutaneous leishmaniasis. Braz. J. Med. Biol. Res. 33:317.
77. Tsagozis P., E. Karagouni and E. Dotsika. 2005. Function of CD8+ T lymphocytes in a self-curing mouse model of visceral leishmaniasis. Parasitol. Int. 54:139.
78. Tsagozis P., E. Karagouni and E. Dotsika. 2003. CD8(+) T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis. Parasite Immunol. 25:569.
79. Sharma M.C., A.K. Gupta, N. Verma, V.N. Das, R. Saran and S.K. Kar. 2000. Demonstration of Leishmania parasites in skin lesions of Indian post kala-azar dermal leishmaniasis (PKDL) cases. J. Commun. Dis. 32:67.
80. Ismail A., A.M. El Hassan, K. Kemp, S. Gasim, A.E. Kadaru, T. Moller, A. Kharazmi and T.G. Theander. 1999. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J. Pathol. 189:615.